TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00818961

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: alemtuzumab
Description: 43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: graft-versus-tumor induction therapy
Description: curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: in patients with Cd20+ malignancies: rituximab 375 mg/m\*2 day -13. rituximab 1000 mg/m\*2 on days, -6, +1, +8.

Intervention type: DRUG
Group type: OTHER
Intervention: busulfan
Description: For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
Study: NCT04682275

Intervention type: OTHER
Group type: OTHER
Intervention: Psychological measurements
Description: A questionnaire test (Beck depression Inventory) for depression was performed.
Study: NCT02866175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: prasugrel 5mg or 10 mg once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: prasugrel 5mg or 10 mg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor 90 mg twice-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ticagrelor 90 mg twice-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist
Description: VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
Study: NCT01584336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LATG
Description: 1. After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~2. The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~3. The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~4. After then, the operator performs the jejunojejunostomy.
Study: NCT02780713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant A
Description: AZD9496 Variant A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant B
Description: AZD9496 Variant B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant C
Description: AZD9496 Variant C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant D
Description: AZD9496 Variant D
Study: NCT01120015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein
Description: Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
Study: NCT04240639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuroShell particle infusion
Description: Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
Study: NCT01329874

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Type of block injection
Description: Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
Study: NCT00802035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen IR
Description: 30 mg; single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen IR
Description: 30 mg; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen ER
Description: 30 mg; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen ER
Description: 30 mg; single dose
Study: NCT04819516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-intensity focused ultrasound therapy
Description: Patients will receive high-intensity focused ultrasound therapy in local site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab plus regorafenib
Study: NCT05235893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology was applied to soles of the babies in the second study group during 5-7 minutes, three minutes before the painful procedure was started by a physiotherapist, certificated in reflexology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose %24
Description: The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo care
Description: The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music
Study: NCT02128373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Health care provided by physician, physician's nurse, and social worker

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Health care provided by physician, physician's nurse, and social worker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted intervention
Description: Caregiver will virtually attend visit using the CLOSER intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distress Thermometer
Description: Average score of a one item scale (range 0-10) where higher scores indicate more distress

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distress Thermometer
Description: Average score of a one item scale (range 0-10) where higher scores indicate more distress

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Profile of Mood States (POMS-B)
Description: average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profile of Mood States (POMS-B)
Description: average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life: Functional Assessment in Cancer Therapy - (FACT)
Description: Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life: Functional Assessment in Cancer Therapy - (FACT)
Description: Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tension-Anxiety Subscale
Description: six item scale which asks to qualitatively describe which areas in you life are causing stress

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tension-Anxiety Subscale
Description: six item scale which asks to qualitatively describe which areas in you life are causing stress
Study: NCT04219124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMP oral tablet
Description: Dapagliflozin 10 MG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablets
Study: NCT01631149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgical block (rocuronium; atracurium/mivacurium)
Description: The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgical block (rocuronium; atracurium/mivacurium)
Description: A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
Study: NCT04027725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
Study: NCT01587846

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of L.reuteri in children with abdominal pain
Description: Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of placebo in children with abdominal pain
Description: Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of L.reuteri in children with constipation
Description: Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of placebo in children with constipation
Description: Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
Study: NCT01545037

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
Description: Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
Study: NCT00818961

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: 750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate
Description: For patients with CLL, NHL \& HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate
Description: 5 mg/m2 administered on days +1, +3 and +6

Intervention type: DRUG
Group type: OTHER
Intervention: tacrolimus
Description: 0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO

Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic bone marrow transplantation
Description: Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
Study: NCT04373538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-C for sleep and circadian function + Memory Support
Description: The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
Study: NCT00683826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Leucine 8gr
Description: Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid meal
Description: Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Leucine 4g
Description: Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
Study: NCT01423630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics and fruit fibre
Description: probiotics and fruit fibre
Study: NCT03583255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete resistance training and moderate intensity walking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Complete resistance training and moderate intensity walking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT00717860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin acetate
Description: Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Micafungin sodium
Description: Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
Study: NCT00886444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferucarbotran (Resovist)
Description: single time intravenous bolus injection of a contrast agent
Study: NCT00427921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 160 mg loading dose, 80 mg at week 2, 40 mg every other week
Study: NCT02315404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAP
Description: CAP fitted to the end of the endoscope

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CAP
Description: CAP fitted to the end of the endoscope
Study: NCT01250574

Intervention type: OTHER
Intervention: CD64 and Procalcitonin
Description: Blood tests taken before and regularly after surgery or other treatment.

Intervention type: OTHER
Intervention: CD64 and Procalcitonin
Description: Blood tests taken before and regularly after surgery or other treatment.
Study: NCT02252393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RARC with IUD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RARC with EUD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative complication management/prevention
Description: Undergo RARC with IUD
Study: NCT04536272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: Administration of LMWH guided by weight and renal function during ECLS.
Study: NCT04332042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
Study: NCT01814592

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally partial thickness flap plus connective tissue
Description: The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally mucosal thickness flap
Description: The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
Study: NCT01936025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04696666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTYLAN (Sodium Hyaluronate 80mg/50ml)
Description: The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.